Annexuzlimab is a new specific monoclonal antibody designed to treat autoimmune diseases.

Its target is annexin-1, which is over-expressed in autoimmune disease, and is a key factor in the human immune system.

In extensive non-clinical testing, annexuzlimab has shown significant activity in rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.

Annexuzlimab, which has been humanised, has the potential to become a major new agent in the treatment of these complex conditions.

Latest News

November 2017

MedAnnex partners with University College London (UCLC) to further explore annexuzlimab’s potential as a new therapeutic for SLE

November 2017

MedAnnex confirms a 4-year Medical Research Scotland PhD studentship (Glasgow University), exploring the role of annexin and mechanism of action of annexuzlimab in chronic inflammatory disease